Luke Evnin, Ph.D., is a co-founder and current Chairman of Maverick Therapeutics. He co-founded MPM Capital with Ansbert Gadicke in 1997 and opened the San Francisco office in 1999. The MPM team they have led has been the inspiration and driving force behind building numerous successful biotech companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis:NVS , Epizyme (EPZM), Idenix (acquired by Merck:MRK), Pacira (PCRX), Pharmasset (acquired by Gilead:GILD) and Radius (RDUS). Luke was the lead investor and has served on the boards of several of MPM’s most successful investments including CoStim Pharmaceuticals, Idun Pharmaceuticals, and Pacira and is the current chairman of several of MPM’s investments in the immune-oncology arena in addition to Maverick including Potenza Therapeutics, Tizona Therapeutics, Oncorus, and Amphivena Therapeutics.
Prior to co-founding MPM, Luke honed his skills as a venture capitalist beginning in 1990 at Accel Partners where he focused on emerging healthcare companies. Luke has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. Luke also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, serves on the External Advisory Boards for QB3 at UCSF, and Advisory Board for Mission Bay Capital.